Orchestra BioMed Holdings (OBIO) Change in Accured Expenses (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Change in Accured Expenses data on file, last reported at -$3.1 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 1413.86% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 50.3% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, up 63.89% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.1 million, down from $566000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for OBIO reached as high as $3.7 million in Q2 2024 and fell as low as -$3.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $486705.9 across 5 years, with a median of $566000.0 in 2025.
• Across the five-year window, Change in Accured Expenses jumped 8214.17% in 2022 and plunged 1413.86% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.1 million in 2022, then tumbled by 53.4% to $493000.0 in 2023, then tumbled by 244.42% to -$712000.0 in 2024, then surged by 179.49% to $566000.0 in 2025, then slumped by 640.28% to -$3.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$3.1 million in Q1 2026, $566000.0 in Q4 2025, and $3.4 million in Q3 2025.